Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN)

CAPS Rating: 3 out of 5

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

Recs

0
Player Avatar jahartmu (95.01) Submitted: 6/22/2010 10:45:53 PM : Outperform Start Price: $18.50 AMLN Score: +16.10

Promising Lilly partnership, cash flows trending positive, and products in development that will be game-changing for the treatment of diabetes.

Featured Broker Partners


Advertisement